or Try an Advanced Search...

    Technical Analysis for RNXT - RenovoRx, Inc.

    Grade Last Price % Change Price Change
    C 1.16 -2.52% -0.03
    RNXT closed up 7.21 percent on Wednesday, November 20, 2024, on 6.42 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical RNXT trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish -2.52%
    Pocket Pivot Bullish Swing Setup -2.52%
    Volume Surge Other -2.52%
    Gapped Up Strength -2.52%
    Upper Bollinger Band Touch Strength -2.52%
    20 DMA Support Bullish 4.50%
    Doji - Bullish? Reversal 4.50%
    Gapped Up Strength 4.50%
    Upper Bollinger Band Walk Strength 8.41%
    Gapped Up Strength 8.41%
    Older End-of-Day Signals for RNXT ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 2 hours ago
    Rose Above Previous Day's High about 2 hours ago
    Rose Above Upper Bollinger Band about 2 hours ago
    200 DMA Resistance about 2 hours ago
    2x Volume Pace about 2 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RNXT Chart by TradingView
    Basic chart:

    Profile

    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Evofosfamide Gemcitabine Gastrointestinal Cancer Locally Advanced Pancreatic Cancer

    Is RNXT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 19 RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
    Jul 31 RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
    Jul 8 RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
    Jun 26 University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
    May 21 Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
    See more RNXT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.35
    52 Week Low 0.5488
    Average Volume 39,045
    200-Day Moving Average 1.21
    50-Day Moving Average 1.04
    20-Day Moving Average 1.05
    10-Day Moving Average 1.11
    Average True Range 0.09
    RSI (14) 66.10
    ADX 17.69
    +DI 23.85
    -DI 13.55
    Chandelier Exit (Long, 3 ATRs) 0.98
    Chandelier Exit (Short, 3 ATRs) 1.03
    Upper Bollinger Bands 1.19
    Lower Bollinger Band 0.91
    Percent B (%b) 0.98
    BandWidth 26.70
    MACD Line 0.03
    MACD Signal Line 0.02
    MACD Histogram 0.01
    Fundamentals Value
    Market Cap 20.02 Million
    Num Shares 16.8 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -1.29
    Price-to-Sales 0.00
    Price-to-Book 4347.25
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.36
    Resistance 3 (R3) 1.35 1.30 1.33
    Resistance 2 (R2) 1.30 1.25 1.30 1.32
    Resistance 1 (R1) 1.24 1.23 1.27 1.25 1.31
    Pivot Point 1.19 1.19 1.20 1.19 1.19
    Support 1 (S1) 1.13 1.14 1.16 1.14 1.07
    Support 2 (S2) 1.08 1.12 1.08 1.06
    Support 3 (S3) 1.02 1.08 1.05
    Support 4 (S4) 1.03